Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

In the realm of pharmaceutical patent litigation, settlement agreements between branded and generic pharmaceutical companies are frequently used to resolve disputes before, during, and after trials in ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.

Despite the increasing use of hybrid clinical trials, most participants still don’t have a say in how or where their study visits take place. Research sites, meanwhile, are left juggling dozens of ...

Multiregional clinical trials (MRCTs) have become a cornerstone of global drug development, enabling simultaneous evaluation of therapies while adhering to rigorous standards required for regulatory ...